Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. Transactions on Cancer
  4. Vol 4, Issue 1, 2023

Research progress on the mechanism and countermeasures of acquired EGFR resistance

Download as PDF

DOI: 10.23977/tranc.2023.040103 | Downloads: 16 | Views: 425

Author(s)

Hongling Fu 1, Peng Xu 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, China
2 Department of Oncology, Shaanxi Provincial Hospital of Chinese Medicine, Xi'an, China

Corresponding Author

Hongling Fu

ABSTRACT

Epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors (TKI) have transformed traditional cancer treatment and brought good news to patients with non-small cell lung cancer. However, drug resistance problems arise one after another. Based on further exploration of the mechanism of EGFR resistance and corresponding therapeutic strategies, the author reviewed relevant literature, classified and summarized it, providing ideas for solving the clinical problem of EGFR resistance and providing hope for tumor patients.

KEYWORDS

Non-small cell lung cancer, drug resistance mechanism, epidermal growth factor receptor-tyrosine kinase inhibitors, drug resistance strategy

CITE THIS PAPER

Hongling Fu, Peng Xu, Research progress on the mechanism and countermeasures of acquired EGFR resistance. Transactions on Cancer (2023) Vol. 4: 15-20. DOI: http://dx.doi.org/10.23977/tranc.2023.040103.

REFERENCES

[1] Zhang S, Sun K, Zheng R, et al. Cancer incidence and mortality in China, 2015. J Nat Cancer Cent, 2021, 1(1): 2-11. 
[2] Zhang Mengru, Cao Dedong, Ge Wei. Research progress on drug resistance of EGFR-TKIs in non-small cell lung cancer and treatment after drug resistance [J]. Chinese Journal of Medicine, 2019, 18(30):50-52+59. 
[3] Yu T, Xia Q, Gong T, et al. Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR[J]. 2020. 
[4] Shuaiyong Q U, Chunzheng M A. Mechanism and Research Progress on Anti-tumor Effect of Strengthening the Body Resistance Chinese Herbs[J]. Chinese Medicine Modern Distance Education of China, 2018.
[5] Pan L. Mechanism and therapeutic strategy of EGFR-TKI resistance in non-small cell lung cancer [J]. Journal of Medical Information, 2017, 34(07):1-5. 
[6] Park H-R, Kim TM, Lee Y, Kim S, Park S, Ju YS, Kim M, Keam B, Jeon YK, Kim D-W, Heo DS, Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFRT790M-mutant non–small cell lung cancer, Journal of Thoracic Oncology (2021). 
[7] Yang L ,  Ma H ,  Liu G E . Research progress on the relationship and mechanism of LncRNA in EGFR-TKIs resistance non-small cell lung cancer[J]. Chinese Journal of Cancer Prevention and Treatment, 2018, 25(6):449-454.
[8] Danlei Yu, Wen Zhao, Karin A Vallega, Shiyong Sun, Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling, Lung Cancer:Targets and Therapy(2021). 
[9] Ai Xin, Wang Yan. Research progress of epigenetic mechanism in acquired drug resistance of targeted therapy in non-small cell lung cancer [J]. Chinese Journal of Lung Cancer, 2015, 24(10):705-713. 
[10] Pengfei W U, Zhu Y, Yang C,et al. The Mechanism and Countermeasures on the Secondary Resistance of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI)[J]. Anti-tumor Pharmacy, 2015.
[11] Nishihara S.; Yamaoka T.; Ishikawa F.; Ohmori T, et al; Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an EGFR-Activating Mutation. Cells2022, 11, 2201. https://doi. org/10. 3390/cells 11142201
[12] Carlo, Genova, Erika, et al. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer[J]. Expert Opinion on Pharmacotherapy, 2016.
[13] Luw W. EGFR-TKIs in the treatment of non-small cell lung cancer [J]. Journal of Clinical Rational Drug Use, 2016, 14(10):173-175. 
[14] YujunZhang, Liwen Xiong, Fangfang Xie, Xiaoxuan Zheng, et, al, Next-generation sequencing of tissue and circulating tumor DNA:Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer, Original Research, 2021, dol:10. 1003/cam4. 3948. 
[15] Yu Han, Liu Likun, Hao Shulan. Research progress of PI3K/AKT signaling pathway and Traditional Chinese medicine therapy in colorectal cancer [J]. Clinical Research of Traditional Chinese Medicine, 2017, 13(35):144-148. 
[16] Shaojia Wang, Chao Liu, Qing Lei, et, al, Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells, Respiratory Research (2021) 22:146. 
[17] Tsubata, Y.; Tanino, R.; Isobe, T. Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance. Cells2021, 10, 3192. 
[18] Liang C X, Shi Y K, Han X H. Progress in research of drug resistance of non-small cell lung cancer to targeted therapy and the countermeasures[J]. Chinese Journal of New Drugs, 2016.
[19] Liu Y, Lai M, Li S, et al. LS‐106, a novel EGFR inhibitor targeting C797S, exhibits anti‐tumor activities both in vitro and in vivo[J]. Cancer Science, 2021. 
[20] Liu S Y, Zhang J T, Wu Y L. Review and interpretation of important clinical studies on non-small cell lung cancer in 2020 [J]. Journal of Evidence-based Medicine, 201, 21(04):240-249. 
[21] Chen S, Xiang T, Lu W, Hong S, Li Y, Lu Y, Zhang Q, Chen Y, Zhou S, Wang G, Zhang Z, Cai Y. Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification: A case report. Medicine 2021; 100:8(e24380). 
[22] Li Yong, Long Yong, Zhao Chong, et al. Efficacy of EGFR-TKIs combined with antiangiogenic drugs in treatment of advanced EGFR-mutant non-small cell lung cancer [J]. Chinese Journal of General Practice, 2022, 25(08):1007-1013. 
[23] Jin Qianchen, Jiang Jianing, Lv Jinyan, et al. Atzumab and bevacizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer after EGFR-TKIs resistance: a case report and literature review [J]. Chinese Journal of Medical Sciences, 2015, 11(04):239-241. 
[24] Zhang Guixing, Tian Fei, Qu Ziyi, et al. Research Progress of Traditional Chinese medicine combined with EGFR-TKIS in treatment of non-small cell lung cancer [J]. Henan Journal of Traditional Chinese Medicine, 2019, 41(08):1281-1284.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 429
Visits: 28644

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.